Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Crossject Logo
Crossject Growth Score
67
CB Rank
155638
Heat Score
53
Crossject specializes in manufacturing and marketing needleless drug self-injection.
Founded
obfuscation
PublicPost-IPO Debt Dijon, Bourgogne, France51-100 www.crossject.com/en
Manufacturing
Overview

Crossject
Total Funding
obfuscation
Growth Score
67
Heat Score
53

Total Funding
obfuscation
obfuscation
Post-IPO Debt raised
obfuscation
Growth Score67
-11 pts
in past quarter
Heat Score 53
-3 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Crossject

CB Rank
155638
Crossject specializes in manufacturing and marketing needleless drug self-injection.
Founded
obfuscation
PublicPost-IPO Debt Dijon, Bourgogne, France51-100 www.crossject.com/en
Manufacturing

Funding Rounds

Post-IPO Debt
OBF
in
obfuscation
Post-IPO Debt
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation

Key People

  • Photo of Patrick Alexandre
    Patrick Alexandre: Founder and CEO
    Past Role: URGO Medical North America, Industrial Department (Charge de Missions)
  • Photo of Tony Tipton
    Tony Tipton: COO - US
    Past Role: Xequel Bio, Chief Commercial & Operating Officer

Details

Legal Name Crossject SA
Operating Status Active
Stock Symbol  EPA:ALCJ
Company Type For Profit
Founders  Patrick Alexandre
About the Company
Crossject specializes in manufacturing and marketing needleless drug self-injection.
Phone Number +33 (0)3 80 54 98 50
Predictions & Insights

Growth Insight

See this Growth Insight
Crossject is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Products & Services

ZENEO® Needle-Free Auto-Injector
A pre-filled, single-use auto-injector that delivers emergency medications without needles, designed for rapid administration in critical situations.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 6
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Debt - Crossject Logo
Post-IPO Debt - Crossject
1
obfuscation
Vatel CapitalPost-IPO Debt
obfuscation
Post-IPO Debt - Crossject Logo
Post-IPO Debt - Crossject
1
obfuscation
Vatel CapitalPost-IPO Debt
obfuscation
Post-IPO Debt - Crossject Logo
Post-IPO Debt - Crossject
1
obfuscation
Vatel CapitalPost-IPO Debt
obfuscation
Post-IPO Debt - Crossject Logo
Post-IPO Debt - Crossject
1
obfuscation
Vatel CapitalPost-IPO Debt
obfuscation
Post-IPO Debt - Crossject Logo
Post-IPO Debt - Crossject
1
obfuscation
Vatel CapitalPost-IPO Debt

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 6
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Debt - Crossject Logo
Post-IPO Debt - Crossject
1
obfuscation
Vatel CapitalPost-IPO Debt
obfuscation
Post-IPO Debt - Crossject Logo
Post-IPO Debt - Crossject
1
obfuscation
Vatel CapitalPost-IPO Debt
obfuscation
Post-IPO Debt - Crossject Logo
Post-IPO Debt - Crossject
1
obfuscation
Vatel CapitalPost-IPO Debt
obfuscation
Post-IPO Debt - Crossject Logo
Post-IPO Debt - Crossject
1
obfuscation
Vatel CapitalPost-IPO Debt
obfuscation
Post-IPO Debt - Crossject Logo
Post-IPO Debt - Crossject
1
obfuscation
Vatel CapitalPost-IPO Debt

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Vatel Capital Logo
Vatel Capital
Yes
Post-IPO Debt - Crossject Logo
Post-IPO Debt - Crossject
—
Vatel Capital Logo
Vatel Capital
Yes
Post-IPO Debt - Crossject Logo
Post-IPO Debt - Crossject
—
Vatel Capital Logo
Vatel Capital
Yes
Post-IPO Debt - Crossject Logo
Post-IPO Debt - Crossject
—
Vatel Capital Logo
Vatel Capital
Yes
Post-IPO Debt - Crossject Logo
Post-IPO Debt - Crossject
—
Vatel Capital Logo
Vatel Capital
Yes
Post-IPO Debt - Crossject Logo
Post-IPO Debt - Crossject
—
Market Intelligence
People
View Profiles & Contacts
Headcount 51-100 Employee Profiles 4 Board Members and Advisors 1 Contacts 8

Employee Profiles

Board Members and Advisors

News

News and Press

News•Mar 25, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Mar 25, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Feb 19, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Nov 14, 2025
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

2,761
48.36%
 in past month

IT Spend

$3.5KThis year, Crossject is projected to spend $3.5K on IT, according to Aberdeen.

Actively Used Products

7Crossject uses 7 technology products and services including HTML5, HubSpot Marketing Hub, and  Bootstrap, according to G2 Stack.

Active Website Tech Count

28Crossject is actively using 28 technologies for its website, according to BuiltWith. These include IPhone / Mobile Compatible, Viewport Meta, and  HSTS.

Total IP

109The intellectual property of Crossject includes 42 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery. Additionally, Crossject has registered 67 trademarks with the most popular class being 'Pharmaceutical, veterinary and sanitary products', according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Crossject's headquarters? Crossject is located in Dijon, Bourgogne, France.Who invested in Crossject? Crossject has 4 investors including Vatel Capital and  Gemmes Venture.When was the last funding round for Crossject? Crossject closed its last funding round on
obfuscation
from a Post-IPO Debt round.Who are Crossject's competitors? Alternatives and possible competitors to Crossject may include SHL Medical, Covis Pharma, and  Eveon.How much funding has Crossject raised to date? Crossject has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(05b78c5 1)
|